Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112104 | 1.00 | CYP1A2 (0.47) | CYP1A2MAOBFBP1ALDH1A1LMNA | |
| SCHEMBL776592 | 0.74 | CYP2C19 (0.35) | ALDH1A1LMNATDP1MEN1KMT2A | |
| SCHEMBL11878598 | 0.72 | CYP1A2 (0.55) | CYP1A2MAOBALDH1A1LMNANFE2L2 | |
| SCHEMBL3848021 | 0.72 | CYP1A2 (0.55) | CYP1A2MAOBALDH1A1LMNANFE2L2 | |
| SCHEMBL3834342 | 0.70 | CYP1A2 (0.53) | CYP1A2MAOBALDH1A1LMNANFE2L2 | |
| SCHEMBL7737180 | 0.70 | CYP1A2 (0.53) | CYP1A2MAOBALDH1A1LMNANFE2L2 | |
| SCHEMBL29091807 | 0.69 | CYP1A2 (0.52) | CYP1A2MAOBALDH1A1LMNANFE2L2 | |
| SCHEMBL477467 | 0.68 | CYP1A2 (0.57) | CYP1A2MAOBALDH1A1LMNATRPA1 | |
| SCHEMBL477645 | 0.68 | CYP1A2 (0.57) | CYP1A2MAOBALDH1A1LMNATRPA1 | |
| SCHEMBL5974340 | 0.68 | CYP1A2 (0.52) | CYP1A2MAOBALDH1A1LMNANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689706-B1 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIV - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2012020961-A3 | PASTE FOR CONTACTS AND SOLAR CELL USING THE SAME | LG INNOTEK CO., LTD. (KR) | 2012-05-10 | — | — | WO | disclosed |
| EP-1841420-B1 | TREATMENT OF DRUG-RESISTANT PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7744889-B2 | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090306207-A1 | Treatment of Drug-Resistant Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-12-10 | — | — | US | disclosed |
| EP-1689706-A4 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1841420-A2 | TREATMENT OF DRUG-RESISTANT PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | ONCONOVA THERAPEUTICS INC. | 2006-12-14 | — | — | US | disclosed |
| EP-1689706-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006074149-A2 | TREATMENT OF DRUG-RESISTANT PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005046599-A2 | ALPHA, BETA-UNSATURATED SULFOXIDES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-0794218-B1 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-0753540-B1 | Polycarbonate resin composition | MITSUBISHI ENG PLASTICS CORP (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6359028-B1 | USED IN MEDICAL EQUIPMENT, DISCOLORATION INHIBITION | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2002-03-19 | — | — | US | disclosed |
| US-6040367-A | EXCELLENT RESISTANCE TO AN IONIZING RADIATION, IN WHICH HETEROCYCLIC COMPOUND CONTAINING OXYMETHYLENE UNITS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5977206-A | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5948838-A | 0.01 TO 5 PARTS BY WEIGHT OF A COMPOUND CONTAINING OXYMETHYLENE UNIT | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0794218-A2 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0753540-A2 | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280746-A1 | (1E)-1-{[(3-amino-4-methoxyphenyl)methyl]sulfinyl}-2-(2,4,6-trimethoxyphenyl)ethene; antiproliferative agents; offers protection from the cytotoxic effects of ionizing radiation and of cytotoxic chemotherapeutic agents | SULT1E1, GSTO1, CCNA1 | CYP1A2 1005/4885MAOB 4276/4885FBP1 2175/4885 |
| US-20090306207-A1 | Treatment of Drug-Resistant Proliferative Disorders | ARSA, KSR1, RPS6KA1 | CYP1A2 3013/4885MAOB 4538/4885FBP1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.